In patients with a recent (within 24 hours) minor ischemic stroke (NIHSS ≤ 5) or high‑risk transient ischemic attack (TIA) and no contraindications, what is the appropriate ticagrelor loading and maintenance dosing, duration of therapy, and major contraindications?

Ticagrelor in Acute Minor Stroke and High-Risk TIA

For patients with minor ischemic stroke (NIHSS ≤5) or high-risk TIA presenting within 24 hours, initiate dual antiplatelet therapy with ticagrelor 180 mg loading dose followed by 90 mg twice daily for 30 days plus aspirin 300-325 mg loading dose followed by 75-100 mg daily, then transition to single antiplatelet therapy.

Dosing Regimen

Loading Doses (Day 1)

• Ticagrelor: 180 mg loading dose 1
• Aspirin: 300-325 mg loading dose 1

Maintenance Dosing (Days 2-30)

• Ticagrelor: 90 mg twice daily 1
• Aspirin: 75-100 mg once daily 1

After 30 Days

• Transition to single antiplatelet therapy (either aspirin 75-100 mg daily OR clopidogrel 75 mg daily) 1

Duration of Therapy

30 days of dual antiplatelet therapy is the recommended duration 1. This differs from aspirin-clopidogrel DAPT, which is typically continued for 21-90 days 2.

Timing of Initiation

• Initiate as early as possible within 24 hours of symptom onset 1
• Must exclude intracranial hemorrhage on neuroimaging before starting 1

Patient Selection Criteria

Appropriate Candidates

• NIHSS ≤5 (mild-to-moderate stroke) 2, 1
• High-risk TIA (ABCD2 score ≥4 or ≥6 depending on guideline) 2, 1
• Non-cardioembolic stroke 2, 3
• Presentation within 24 hours of symptom onset 1, 3

Major Contraindications

Absolute Contraindications

• Intracranial hemorrhage on neuroimaging 1
• Active pathological bleeding 3
• History of intracranial hemorrhage 3
• Planned thrombolysis or thrombectomy 3
• Cardioembolic stroke requiring anticoagulation 2, 1
• Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole) 4

Relative Contraindications/Cautions

• Increased bleeding risk - The THALES trial demonstrated severe bleeding in 0.5% of ticagrelor-aspirin patients versus 0.1% with aspirin alone 3
• Recent major surgery or trauma
• Severe hepatic impairment
• Thrombocytopenia or coagulation disorders

Evidence Quality and Clinical Context

The 2023 World Stroke Organization guidelines 1 provide the most recent comprehensive recommendations, supported by the THALES trial 3, which demonstrated that ticagrelor-aspirin reduced stroke or death at 30 days (5.5% vs 6.6%, HR 0.83, p=0.02) compared to aspirin alone. However, this came at the cost of increased severe bleeding (0.5% vs 0.1%, p=0.001).

The 2021 AHA/ASA guideline 2 gives ticagrelor-aspirin a Class 2b recommendation (may be considered), noting it may increase serious bleeding including intracranial hemorrhage. This more conservative stance reflects the bleeding risk trade-off.

Critical Clinical Pitfalls

Bleeding Risk

The most important caveat is the 5-fold increase in severe bleeding compared to aspirin monotherapy 3. Carefully assess bleeding risk factors before initiating therapy.

NIHSS Threshold Confusion

• Ticagrelor-aspirin is recommended for NIHSS ≤5 2, 1
• Aspirin-clopidogrel is recommended for NIHSS ≤3 2
• This creates a specific niche for ticagrelor-aspirin in patients with NIHSS 4-5

Duration Matters

Do not continue DAPT beyond 30 days - prolonged dual antiplatelet therapy increases hemorrhagic complications without additional benefit 2, 1.

Drug Interactions

Ticagrelor is contraindicated with strong CYP3A4 inhibitors like itraconazole 4. Screen for these medications before prescribing.

Real-World Adoption

Despite guideline recommendations, ticagrelor-aspirin remains underutilized in practice (only 1.3% of eligible patients in one registry study) 5, suggesting implementation barriers including cost and bleeding concerns.

Alternative Consideration

For patients with NIHSS ≤3, aspirin-clopidogrel remains a viable alternative with potentially lower bleeding risk, initiated within 12-24 hours and continued for 21-90 days 2, 1.